Lupus & Rheumatoid Arthritis | Dr. Ye Shuang (Rheumatology) | CMCS Shanghai

About Dr. Ye Shuang

Dr. Ye Shuang is Chief of Rheumatology at Renji Hospital, Shanghai Jiao Tong University School of Medicine — one of China's foremost rheumatology centres and a national reference institution for systemic autoimmune disease, lupus nephritis, and biologic therapy in rheumatology. She is a nationally recognised leader in systemic lupus erythematosus, rheumatoid arthritis, and complex overlap autoimmune syndromes, with particular expertise in biologic and targeted synthetic DMARD therapy, treat-to-target strategies for SLE and RA, and the long-term management of autoimmune disease in young women including fertility preservation and pregnancy planning. Dr. Ye's practice is defined by the philosophy that autoimmune disease management is not about suppressing symptoms — it is about protecting organs, preserving function, and enabling patients to live full lives over decades. Her department at Renji Hospital has established one of China's most comprehensive autoimmune disease programmes, integrating high-resolution musculoskeletal ultrasound, renal biopsy-guided treatment stratification, biologic therapy, and structured long-term surveillance into a unified care pathway for patients with complex multisystem autoimmune disease.

Case Overview

Ms. Isabelle Fontaine, a 28-year-old French teacher based in Shanghai, presented with a three-month history of symmetric polyarthritis, facial butterfly rash, and foamy urine — a combination of symptoms that immediately raised the possibility of more than one autoimmune diagnosis. Laboratory evaluation confirmed the simultaneous presence of SLE-specific antibodies (anti-dsDNA positive at greater than 1:1000, anti-Sm positive, ANA 1:3200) and RA-specific antibodies (anti-CCP greater than 200 U/mL, high-titre rheumatoid factor) — establishing the diagnosis of Rhupus syndrome, the rare but clinically severe overlap of systemic lupus erythematosus and rheumatoid arthritis. Renal biopsy confirmed Class IV lupus nephritis with cellular crescent formation — the most aggressive form of lupus renal involvement, carrying a five-year renal survival rate below 50% without aggressive treatment.

Dr. Ye Shuang led a multidisciplinary team including nephrology and pathology to design an individualised treatment strategy: methylprednisolone pulse therapy followed by oral prednisolone, cyclophosphamide induction for the Class IV nephritis, hydroxychloroquine as backbone therapy for both SLE and RA, and — given the patient's age, fertility priorities, and the inadequacy of conventional DMARDs for the RA component — belimumab biologic therapy targeting the B-lymphocyte stimulator (BLyS) pathway. At three months, SLEDAI-2K score had fallen from 22 to 4, DAS28 from 6.8 to 2.4, anti-dsDNA titres had declined, complement levels had normalised, and 24-hour urinary protein had reduced from 3.5 g to below 0.5 g. The patient entered a structured long-term management programme including fertility counselling, bone density monitoring, and ophthalmological surveillance.

Patient Background

• Name / Nationality: Ms. Isabelle Fontaine (pseudonym) — French; secondary school teacher based in Shanghai; married, no children; strong fertility preservation priorities
• Age / Sex: 28-year-old female
• Chief Complaint: Bilateral symmetric joint swelling and pain, facial butterfly rash, and foamy urine for 3 months; symptom exacerbation for 1 week
• Articular symptoms: Symmetric swelling and tenderness of bilateral proximal interphalangeal (PIP) joints, metacarpophalangeal (MCP) joints, and wrist joints; morning stiffness exceeding 1 hour
• Systemic symptoms: Butterfly-shaped facial erythema worsening with sun exposure; hair loss; oral ulcers; bilateral lower limb pitting oedema
• Past medical history: No prior autoimmune diagnosis; no drug allergies; no hepatitis or tuberculosis history
• Examination: Butterfly rash across malar eminences and nasal bridge; fusiform swelling of bilateral finger joints; bilateral wrist tenderness; moderate bilateral lower limb pitting oedema; cardiorespiratory and abdominal examination unremarkable

Diagnostic Workup

Autoantibody Profile

• Antinuclear antibody (ANA): 1:3200 — homogeneous and speckled pattern; strongly positive
• Anti-double-stranded DNA (anti-dsDNA): Positive at greater than 1:1000 — SLE-specific antibody; highly elevated titre indicating active disease
• Anti-cyclic citrullinated peptide (anti-CCP): Positive at greater than 200 U/mL — RA-specific antibody; high titre associated with erosive joint disease and poor articular prognosis
• Anti-Sm antibody: Positive — SLE-specific; associated with lupus nephritis and central nervous system involvement
• Rheumatoid factor (RF): High-titre positive — consistent with seropositive RA
• Interpretation: Simultaneous positivity for SLE-specific (anti-dsDNA, anti-Sm) and RA-specific (anti-CCP, RF) antibodies — the serological hallmark of Rhupus overlap syndrome

Inflammatory Markers and Complement

• Erythrocyte sedimentation rate (ESR): 85 mm/h — markedly elevated; systemic inflammation confirmed
• C-reactive protein (CRP): 45 mg/L — significantly elevated
• Complement C3: Significantly reduced — complement consumption indicating active immune complex deposition
• Complement C4: Significantly reduced — consistent with active SLE with complement pathway activation

Urinalysis and Renal Function

• Urinary protein dipstick: 3+ — heavy proteinuria
• 24-hour urinary protein quantification: 3.5 g — nephrotic-range proteinuria; renal involvement confirmed
• Urinary occult blood: 2+ — microscopic haematuria; glomerulonephritis pattern
• Serum creatinine: 110 μmol/L — mildly elevated; early renal impairment

Musculoskeletal Ultrasound (MSUS)

• Bilateral wrist and MCP joints: Marked synovial hypertrophy with Power Doppler signal Grade 2–3 — active synovitis with increased vascularity confirming inflammatory arthritis
• Erosions: Early erosive changes (bite sign) identified at MCP joint margins — indicating structural joint damage already present at diagnosis despite only three months of symptoms
• Bursitis: Bilateral wrist bursitis confirmed
• Significance: Power Doppler Grade 2–3 synovitis with early erosions at presentation indicates aggressive RA requiring early biologic intervention to prevent progressive joint destruction

Renal Biopsy — The Diagnostic and Prognostic Foundation

• Light microscopy: Diffuse proliferative glomerulonephritis — involving greater than 50% of glomeruli; endocapillary and extracapillary proliferation
• Cellular crescents: Present in multiple glomeruli — indicating active, rapidly progressive glomerular injury requiring urgent immunosuppressive intervention
• ISN/RPS classification: Class IV lupus nephritis (diffuse proliferative) — the most severe and most common form of lupus nephritis; associated with the highest risk of end-stage renal disease without aggressive treatment
• Activity index: High — predominantly active lesions with significant potential for reversibility with appropriate therapy

Dr. Ye's diagnostic assessment: The biopsy result changes everything about the urgency of this case. Class IV lupus nephritis with cellular crescents is not a condition we can manage conservatively. Without aggressive immunosuppression within weeks, the crescents will organise into fibrous scars and the renal function will not recover. But this patient also has active RA with early erosions — which means we need to treat two aggressive autoimmune diseases simultaneously, in a 28-year-old woman who wants to have children. Every treatment decision we make has to be evaluated against its impact on her fertility, her bone density, her cardiovascular risk, and her quality of life over the next fifty years. That is the complexity of Rhupus syndrome. It is not just two diseases. It is two diseases in one patient who has a lifetime ahead of her.

Diagnosis and Disease Activity Assessment

Diagnostic Criteria

Systemic lupus erythematosus (SLE): Diagnosed per 2019 EULAR/ACR classification criteria — renal biopsy-confirmed Class IV lupus nephritis (weighted heavily in the scoring system), anti-dsDNA positivity, ANA positivity, malar rash, oral ulcers, and hair loss. Score well above the classification threshold of 10 points.

Rheumatoid arthritis (RA): Diagnosed per 2010 ACR/EULAR classification criteria — symmetric small joint involvement (PIP, MCP, wrist), anti-CCP positivity greater than 200 U/mL (high-titre seropositive), high-titre RF, and symptom duration greater than six weeks. Score of 8/10 — definite RA.

Rhupus syndrome: The simultaneous fulfilment of both SLE and RA classification criteria in a single patient — a rare overlap syndrome occurring in approximately 0.09% of SLE patients and associated with more severe articular damage, higher rates of lupus nephritis, and greater treatment complexity than either disease alone.

Disease Activity Scores at Presentation

• SLEDAI-2K (SLE Disease Activity Index): 22 points — very high disease activity; scores above 20 indicate severe, organ-threatening disease requiring urgent intervention
• DAS28 (Disease Activity Score 28 joints): 6.8 — high disease activity; scores above 5.1 indicate high RA activity requiring treatment escalation

Treatment Strategy and Clinical Course

Phase 1 — Induction of Remission (Weeks 1–4)

The immediate priority was to arrest the Class IV lupus nephritis before irreversible renal scarring occurred. The induction regimen was designed to achieve rapid, deep immunosuppression while minimising cumulative toxicity.

Methylprednisolone pulse therapy: Intravenous methylprednisolone 500 mg daily for three consecutive days — high-dose pulse corticosteroid therapy to rapidly suppress the acute glomerular inflammatory response and halt crescent formation. Followed by oral prednisolone 1 mg/kg/day as the maintenance corticosteroid platform.

Cyclophosphamide (CTX) induction: Intravenous cyclophosphamide 0.5–0.75 g/m² monthly — the standard induction agent for Class IV lupus nephritis per EULAR guidelines. CTX alkylates DNA in rapidly dividing immune cells, depleting the autoreactive B and T cell populations driving glomerular injury. Monthly pulse administration rather than daily oral dosing reduces the cumulative gonadotoxic risk — a critical consideration in a 28-year-old woman.

Hydroxychloroquine (HCQ): Commenced at standard dosing as backbone therapy for both SLE and RA — HCQ reduces SLE flare frequency, protects against lupus nephritis progression, reduces cardiovascular risk, and has modest anti-inflammatory effects in RA. It is the only drug used in both diseases simultaneously and is continued indefinitely in all SLE patients without contraindication.

Renal protection: Irbesartan (angiotensin receptor blocker) commenced to reduce intraglomerular pressure and proteinuria through renin-angiotensin system blockade — a nephroprotective measure independent of immunosuppression.

Bone protection: Calcium and vitamin D supplementation commenced from day one of corticosteroid therapy — corticosteroid-induced osteoporosis is a major long-term complication of SLE management, and prevention must begin at the initiation of steroid therapy, not after bone loss has occurred.

Four-week response: Significant reduction in joint swelling and tenderness; 24-hour urinary protein reduced from 3.5 g to 1.5 g; serum creatinine normalised; complement C3 and C4 beginning to recover; ESR and CRP declining.

Phase 2 — Maintenance Therapy and Biologic Introduction (Month 2 Onwards)

With induction remission achieved, the treatment strategy shifted to long-term maintenance — sustaining disease control while minimising cumulative corticosteroid and cyclophosphamide toxicity, and addressing the RA component that conventional SLE maintenance therapy does not adequately control.

Corticosteroid tapering: Prednisolone tapered progressively to 10 mg/day — the minimum dose required to maintain SLE control while reducing the cumulative risks of infection, osteoporosis, diabetes, and cardiovascular disease associated with long-term high-dose corticosteroids.

Cyclophosphamide to mycophenolate mofetil (MMF) transition: After a cumulative CTX dose of 6 g — the threshold beyond which gonadotoxic risk increases substantially — cyclophosphamide was discontinued and mycophenolate mofetil 1.5 g/day commenced as the maintenance immunosuppressant for lupus nephritis. MMF selectively inhibits lymphocyte proliferation with a more favourable toxicity profile than CTX for long-term use.

Belimumab biologic therapy: Dr. Ye introduced belimumab — a monoclonal antibody targeting B-lymphocyte stimulator (BLyS, also known as BAFF) — as the biologic component of the maintenance regimen. Belimumab is the first biologic agent approved globally for the treatment of SLE, and the first approved specifically for active lupus nephritis (BLISS-LN trial). By blocking BLyS, belimumab reduces the survival and differentiation of autoreactive B cells — the primary source of the pathogenic autoantibodies (anti-dsDNA, anti-Sm) driving both the systemic and renal manifestations of SLE. In Rhupus syndrome, belimumab addresses the SLE component while allowing co-administration of RA-targeted therapy if required.

Dr. Ye's treatment rationale: Belimumab changes the treatment equation for young women with SLE in two important ways. First, it reduces the cumulative corticosteroid dose required to maintain disease control — and in a 28-year-old woman, every milligram of prednisolone saved over the next thirty years translates directly into preserved bone density, reduced cardiovascular risk, and a better quality of life. Second, it specifically targets the B cell pathway that drives anti-dsDNA production and lupus nephritis — which means it addresses the root cause of the renal disease rather than just suppressing the immune system broadly. For a patient with Class IV nephritis who has already received cyclophosphamide, belimumab is not an add-on. It is the cornerstone of the long-term strategy.

Three-month response assessment: Anti-dsDNA antibody titres significantly reduced; complement C3 and C4 normalised; 24-hour urinary protein below 0.5 g (complete renal response); SLEDAI-2K score reduced from 22 to 4 (low disease activity); DAS28 reduced from 6.8 to 2.4 (low disease activity, approaching remission); ESR and CRP normalised.

Long-term Management and Surveillance

Fertility Counselling and Pregnancy Planning

With the patient in sustained low disease activity at six months, Dr. Ye initiated structured fertility counselling — a critical component of long-term management in young women with SLE. Pregnancy in SLE carries significant risks including lupus flare, pre-eclampsia, foetal growth restriction, and neonatal lupus — but these risks are substantially reduced when disease has been in remission for at least six months before conception and when the pregnancy is managed by a multidisciplinary team including rheumatology, obstetrics, and neonatology.

Mycophenolate mofetil — teratogenic and absolutely contraindicated in pregnancy — was transitioned to azathioprine (AZA), which has an established safety profile in pregnancy and is compatible with breastfeeding. Belimumab was planned for discontinuation three months before attempted conception per current guidelines. Hydroxychloroquine was continued throughout — it reduces the risk of lupus flare during pregnancy and is safe for the foetus.

Complication Surveillance Protocol

• Ophthalmological monitoring: Annual fundoscopy and optical coherence tomography to detect hydroxychloroquine retinal toxicity — a rare but irreversible complication occurring with cumulative doses above 1000 g or in patients with pre-existing renal impairment
• Bone density: Dual-energy X-ray absorptiometry (DEXA) at baseline and annually — monitoring for corticosteroid-induced osteoporosis; bisphosphonate therapy initiated if T-score falls below −2.5
• Cardiovascular risk: Annual assessment of blood pressure, lipid profile, glucose, and body mass index — SLE independently doubles cardiovascular risk, and corticosteroids compound this through dyslipidaemia and glucose intolerance
• Renal surveillance: Three-monthly urinary protein quantification and renal function testing — lupus nephritis relapse occurs in 30–40% of patients within five years and requires prompt re-induction
• Infection monitoring: Vigilance for opportunistic infections given combined immunosuppression — Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole during high-dose corticosteroid and cyclophosphamide phases

Patient Education and Adherence Management

Dr. Ye's team provided structured patient education covering strict photoprotection (SPF 50+ sunscreen and UV-protective clothing — ultraviolet light triggers SLE flares through keratinocyte apoptosis and nuclear antigen release), infection avoidance strategies, medication adherence counselling, and recognition of flare warning signs requiring urgent medical review. Non-adherence to hydroxychloroquine and immunosuppressive therapy is the most common cause of SLE relapse — patient education is not supplementary to pharmacological treatment; it is an integral component of the treatment plan.

Expert Commentary — Dr. Ye Shuang

1. Rhupus Syndrome: Recognising the Overlap Before It Is Too Late

Rhupus syndrome — the simultaneous occurrence of SLE and RA in a single patient — is rare, but its clinical consequences are disproportionate to its prevalence. Patients with Rhupus have higher rates of lupus nephritis, more severe articular erosions, and greater treatment complexity than patients with either disease alone. The diagnostic challenge is that the two diseases share clinical features — symmetric polyarthritis, fatigue, and elevated inflammatory markers occur in both — and the presence of one diagnosis can mask the other. The key is the autoantibody profile: anti-dsDNA and anti-Sm are SLE-specific; anti-CCP is RA-specific. When both are present simultaneously in a young woman with polyarthritis and systemic features, Rhupus must be the working diagnosis until proven otherwise. The clinical implication is immediate: treatment must address both diseases from the outset. A regimen designed only for SLE will allow the RA to progress and destroy joints. A regimen designed only for RA will allow the SLE to damage kidneys, brain, and cardiovascular system. Hydroxychloroquine is the only drug that addresses both — which is why it is the non-negotiable backbone of every Rhupus treatment plan.

2. Class IV Lupus Nephritis: The Urgency of Biopsy-Guided Treatment

Lupus nephritis is the most important determinant of long-term prognosis in SLE. Class IV nephritis — diffuse proliferative glomerulonephritis — carries a five-year renal survival rate below 50% without aggressive immunosuppression, and the cellular crescents seen in this patient's biopsy indicate that the glomerular injury is in its most active and most reversible phase. The window for intervention is narrow: crescents that are cellular and active can be resolved with immunosuppression; crescents that have organised into fibrous scars cannot. This is why renal biopsy is not optional in SLE with proteinuria — it is the diagnostic foundation that determines the urgency, intensity, and duration of treatment. A clinical diagnosis of lupus nephritis without biopsy is an incomplete diagnosis. The biopsy tells us not just that the kidney is involved, but how severely, how actively, and how urgently we need to act. In this case, the biopsy result converted a three-month history of proteinuria into a rheumatological emergency requiring pulse corticosteroids and cyclophosphamide within days.

3. Belimumab: Precision Targeting in the Era of Biologic Rheumatology

The introduction of belimumab represents a fundamental shift in SLE management — from broad immunosuppression that affects all immune cells indiscriminately to targeted therapy that specifically depletes the autoreactive B cells driving the disease. BLyS is the survival signal that prevents autoreactive B cells from undergoing apoptosis — without BLyS, these cells die and the autoantibody production that drives SLE manifestations declines. Belimumab blocks this signal selectively, reducing anti-dsDNA titres, complement consumption, and lupus nephritis activity without the broad immunosuppressive toxicity of cyclophosphamide or high-dose corticosteroids. For young women with SLE who face decades of treatment, the cumulative toxicity of conventional immunosuppression — osteoporosis, premature ovarian insufficiency, infection, malignancy — is as important a clinical problem as the disease itself. Belimumab reduces the corticosteroid dose required to maintain disease control, reduces the frequency of severe flares, and reduces the cumulative cyclophosphamide exposure — translating directly into better long-term outcomes for patients who will live with this disease for fifty years or more.

4. Treat-to-Target: The Standard That Prevents Irreversible Damage

Treat-to-target is not a slogan. It is the clinical framework that prevents the gradual accumulation of irreversible organ damage that defines the long-term prognosis of both SLE and RA. In RA, the target is DAS28 remission (below 2.6) or low disease activity (below 3.2) — because sustained high disease activity predicts progressive joint erosion, functional disability, and cardiovascular mortality. In SLE, the target is clinical remission per DORIS criteria or, at minimum, lupus low disease activity state (LLDAS) — because sustained high SLEDAI scores predict cumulative organ damage accrual, including renal failure, neuropsychiatric disease, and premature atherosclerosis. The treat-to-target approach requires regular, structured disease activity assessment — not just asking the patient how they feel, but measuring SLEDAI, DAS28, complement, anti-dsDNA, and urinary protein at every visit and adjusting therapy when targets are not met. In Rhupus syndrome, we are simultaneously pursuing two targets in two diseases. That requires more frequent monitoring, more complex treatment decisions, and a longer-term perspective than either disease alone. It also requires a patient who understands why the monitoring matters — which is why patient education is not supplementary to treatment. It is treatment.

How CMCS Shanghai Coordinated This Case

CMCS Shanghai supported Ms. Fontaine from initial symptom presentation through long-term surveillance programme establishment, including: urgent coordination of comprehensive autoantibody panel, inflammatory markers, complement levels, and urinalysis with same-week results and bilingual interpretation; specialist referral to Dr. Ye Shuang at Renji Hospital's Department of Rheumatology with priority MDT scheduling; coordination of musculoskeletal ultrasound with Power Doppler assessment and renal biopsy scheduling with bilingual consent support; bilingual interpretation throughout all MDT discussions involving rheumatology, nephrology, and pathology; real-time translation of renal biopsy pathology report with clinical significance explained to the patient and her husband; coordination of methylprednisolone pulse therapy admission and cyclophosphamide infusion scheduling with bilingual nursing support; weekly bilingual updates during the four-week induction phase covering laboratory trends, side effect management, and treatment response; belimumab infusion scheduling and tolerability monitoring with bilingual pharmacy counselling; coordination of three-month restaging assessment including anti-dsDNA, complement, 24-hour urinary protein, SLEDAI, and DAS28 with results communicated to the patient's rheumatologist in France; fertility counselling session coordination with bilingual reproductive endocrinology consultation; mycophenolate to azathioprine transition planning with teratogenicity counselling in English and French; annual ophthalmological surveillance scheduling for hydroxychloroquine retinal monitoring; DEXA bone density scanning coordination and bisphosphonate therapy initiation if indicated; and establishment of a long-term surveillance protocol with direct communication between Dr. Ye's team and the patient's treating rheumatologist in Paris.

For international patients with systemic lupus erythematosus, rheumatoid arthritis, complex autoimmune overlap syndromes, or lupus nephritis requiring expert rheumatological evaluation in Shanghai, Dr. Ye Shuang's team at Renji Hospital represents autoimmune disease expertise at the international frontier — combining biopsy-guided treatment stratification, biologic precision therapy, and comprehensive long-term surveillance to protect organs, preserve fertility, and enable patients to live full lives with chronic autoimmune disease. CMCS ensures that expertise is accessible: in the patient's language, with overseas physicians informed at every step, from the first autoantibody panel through decades of long-term management.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.